//

Investor PresentationApril 2021

//

Forward-Looking Statements Disclosure

12 April 2021 2

This presentation will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act

of 1995. All statements other than statements of historical facts contained in this presentation, including statements

regarding our future results of operations and financial position, business strategy, prospective products, availability of

funding, ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements, the scope,

progress, results and costs of developing our products or any other future products, the potential market size and size of the

potential patient populations for our products, the timing and likelihood of success of obtaining product approvals, plans and

objectives of management for future operations, the scope of protection we are able to establish and maintain for

intellectual property rights covering our products, and future results of anticipated products, are forward-looking statements.

These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual

results, performance or achievements to be materially different from any future results, performance or achievements

expressed or implied by the forward-looking statements. All statements made on this call that do not relate to matters of

historical fact should be considered forward-looking statements. Factors that may cause results to differ from these forward-

looking statements are discussed under the Forward-Looking Statements section in the company’s most recent 10K and

other periodic filings with the Securities and Exchange Commission (SEC).

Any forward-looking statements provided during this presentation, including projections for future performance, are based

on management’s expectations as of today. Acutus undertakes no obligation to update these statements, except as

required by applicable law.

Leading the Charge in the EP Revolution

4/12/2021 3

We are a therapy management company

developing comprehensive and innovative solutions

to treat cardiac arrythmias

Contact

Diagnostic

Solutions**

Gold Tip Ablation Therapy*

Access Guides & Sheaths

High Density Non-Contact Advanced Mapping

Ultrasound Integrated 3DNon-Contact

Mapping SystemStrategic

Partnerships

Expert Clinical

& Product

Support

* CE Mark - Not approved for use in the United States

** - Some products not manufactured by Acutus Medical

Our vision is to become the partner-of-choice for

electrophysiologists and hospitals around the world

through our portfolio of access, diagnostic,

imaging, and therapy products

We will execute our strategy and drive shareholder

value through technology and innovation leadership,

commercial execution, and operational excellence

//

Our Markets are Large, Growing, and Underpenetrated

12 April 2021 4

~$5.7 Billion*~1.1 million

ablation procedures

10-15%Annual growth rate of

ablation procedures

worldwide (2015-2019)

Progressive disease,

function of aging

Western

lifestyleIncreasing utilization of

self monitoring devices

Well established

reimbursement in

developed markets

Key drivers: Growing incidence and diagnosis of cardiac arrhythmias

Sources: Electrophysiology Mapping and Ablation Devices, Market Insights, US. Decision Resources Group M360EP0059, June 2019, American Hospital Association, Center

for Disease Control and Prevention, European Heart Rhythm Association, Internal Estimates

<5%Current global

penetration of

prevalence pool

*Estimated 2019 value of disposables segment

//

Unmet Need: Lack of Options for Complex Patient Population

12 April 2021 5

>50% of procedures for

paroxysmal (early/simple

patients); while complex patients

represent nearly ~70% of

prevalence pool

Sources: Electrophysiology Mapping and Ablation Devices, Market Insights, US. Decision Resources Group M360EP0059, June 2019, American Hospital Association, Center

for Disease Control and Prevention, European Heart Rhythm Association, Internal Estimates

Complex patient population left with few good options

Landmark studies have

shown success rates at

~50% (defined as

freedom from atrial

fibrillation at 12-months)

Procedure times can

range 2-6 hours

Few dedicated

treatment options for

complex patients

Lengthy and

complicated nature of

conventional mapping

and ablation

techniques

Relatively poor

clinical outcomes

//

Unique Electrophysiology Therapy Guidance Platform

12 April 2021 6

Workstation and Console

48 High FidelityLow Impedance Electrodes

48 UltrasoundTransducers

0.032” (0.81mm)Guidewire Compatible

Non-Contact 3D Imaging and Mapping Catheter Compatible with Conventional Mapping Catheters

➢ Whole chamber anatomy and electrical maps in under 3 minutes➢ Facilitates map, ablate, re-map

➢ Open platform➢ Workhorse system for less complex cases

// 12 April 2021 7

Impediments To

PenetrationParoxysmal AF Persistent AF

Long Standing

Persistent AFAtypical Flutter

Complex

Tachycardia

Other Atrial

Arrhythmias

Ventricular

Tachycardia

(Research) (2)

~23% ~15% ~6% ––––––––––––––– Remaining ~48% –––––––––––– ~8%

Long Procedures

Procedures of

Unpredictable Duration

Poor Outcomes at

Ablation

Extreme MD Skill

Required

General Cardiologists

Reluctant to Refer

High Benefit Significant Benefit Benefit

Atrial Fibrillation Supraventricular Tachycardias

Percentages above based on company estimates of ~1,081k WW electrophysiology procedures in 2019 including 475k atrial fibrillation procedures (of which 53% were for paroxysmal atrial

fibrillation, 33% were for persistent atrial fibrillation and 14% were for long-standing persistent atrial fibrillation), 516k SVT procedures and 90k VT procedures

(1) Based on internal Company estimates

(2) AcQMap catheter is not currently indicated for use in the ventricle

Why Is the Market Less Than 5% Penetrated?(1)

How and Where Acutus Can Add Value / Solve Problems

// 12 April 2021 8

Variable

Acutus

UNCOVER AF

12M [1]

N = 127

Biosense

PRECEPT

15M [2]

N = 381

AtriCure

CONVERGE

Endo Only

12M [3]

N = 51

AtriCure

CONVERGE

Convergent

12M [3]

N = 102

Abbott

STAR AF II

PVI

12M [4]

N = 61

Abbott

STAR AF II

PVI + CFAE

12MN = 244

Abbott

STAR AF II

PVI + Lines

12MN = 244

Patient Population Persistent AF Persistent AFPersistent & Long-Standing

Persistent AFPersistent AF

Re-ablation allowed in “blanking period” None 3 - 6 Months None None 3 Months 3 Months 3 Months

Freedom from AF > 30 s after one

procedure, with or without AAD73% NR 51% 71% 61% 54% 50%

Freedom from AF > 30 s after multiple

procedures, with or without AAD*93% NR NR NR 79% 70% 70%

Freedom from AF/AT/AFL > 30 s after

one procedure, with or without AAD69.2% 61.7% 49% 67.5% 52% 48% 44%

UNCOVER AF (AcQMap): We believe fundamentally different mapping approach & therapy strategy (non-contact

mapping & map/treat/re-map strategy) leads to improved success rates 1: Willems et al; Charge Density Mapping for Atrial Fibrillation:Circ Arrhythm Electrophysiol. 2019;12:e007233.

2: Mansour M, et. al; Persistent atrial fibrillation ablation with contact force sensing catheter: The prospective multicenter PRECEPT Trial, JACC: Clinical Electrophysiology (2020)

3: De Lurgio D et. al; Hybrid Convergent Procedure: Epicardial and Endocardial Ablation for the Treatment of Persistent Atrial Fibrillation -CONVERGE Randomized Controlled Clinical Trial Results, HRS Late-Breaking Clinical Trials (2020)

4: Verma A, et al; Approaches to Catheter Ablation for Persistent Atrial Fibrillation N Engl J Med 2015;372:1812-22. Estimated from KM curve data available in NEJM

*Outcome comparisons are difficult due to difference in the detailed effectiveness outcome definitions

NR = Not Reported

Acutus Comparative Outcomes for Persistent AF*Meaningful Clinical Improvement vs. Stagnant Standard of Care

//

Traditional Approaches and Products in Persistent AF Yield Disappointing Results

12 April 2021 9

50% 49%46%

39%

29%27%

12.5%

0%

25%

50%

75%

100%

Abbott

N = 244Atricure

N = 51

Abbott

N =244

Abbott

N = 61Atricure

N = 102Acutus

N = 127

STAR-AF 2 [4]

PVI + Lines

CONVERGE [3]

PVI – Control

Arm

STAR-AF 2

PVI + CFAE

STAR-AF 2

PVI OnlyCONVERGE

Therapy Arm

UNCOVER AF [1]

PVI + Core-To-

Boundary

Individualized Tx

INVESTIGATOR

SPONSORED [2]

PVI + Core-To-

Boundary

Individualized Tx

Freedom from AF may be maintained for a longer

duration with a Core-to-Boundary Strategy

Failure back into AF within 12 months in significant trials

(using contact mapping and traditional ablation strategies)

73%SUCCESS

87.5%SUCCESS

1: Willems et al; Charge Density Mapping for Atrial Fibrillation:Circ Arrhythm Electrophysiol. 2019;12:e007233.

2: Shi, et al. Heart Rhythm. 2021; S1547-5271(21)00136-3 DOI: https://doi.org/10.1016/j.hrthm.2021.02.014

3: De Lurgio D et. al; Hybrid Convergent Procedure: Epicardial and Endocardial Ablation for the Treatment of Persistent Atrial Fibrillation -CONVERGE Randomized Controlled Clinical Trial Results, HRS Late-Breaking Clinical Trials (2020)

4: Verma A, et al; Approaches to Catheter Ablation for Persistent Atrial Fibrillation N Engl J Med 2015;372:1812-22. Estimated from KM curve data available in NEJM

*Outcome comparisons are difficult due to difference in the detailed effectiveness outcome definitions

NR = Not Reported

Oxford & Royal

Brompton

N = 40

24

MO

NT

HS

//

Comprehensive Product Portfolio, Transformative Technology for Electrophysiologists

12 April 2021 10

Patient Electrode Kit

Large Bore Steerable Sheath

AcQGuide MAX

Dual Purpose IntroducerAcQRef

Septal CrossingAcQCross Qx

ICE Catheter*Innovative HealthReprocessed

Fixed Curve SheathAcQGuide MINI

Small Bore Steerable SheathAcQGuide FLEX

Diagnostic Mapping Catheters,

Accessories

High Density Atrial /Ventricular Mapping

AcQMap 3D Imaging and Mapping Catheter

Innovative Health Reprocessed*

Ablation CathetersAcQBlate Gold Force Sensing

and Conventional

Partnerships*Stereotaxis

Biotronik

Image Integration*Ϯ

* Partnerships

Ϯ Development, not currently marketed

//

Completing the Continuum: Access, Diagnostics, Therapy, and Monitoring

12 April 2021 11

Transseptal Access Mapping & Diagnostics Therapy Monitoring

AcQ

Cro

ss T

ran

sse

pta

l S

yste

m

AcQ

Cro

ss +

MIN

I

AcQ

Cro

ss +

FL

EX

AcQ

Cro

ss +

VZ

AcQ

Cro

ss +

SW

AcQ

Cro

ss +

AG

AcQ

Cro

ss +

SL

AcQ

Gu

ide

MA

X

AcQ

Gu

ide

VU

E

AcQ

Ma

p C

ath

ete

r

AcQ

Ma

p C

on

so

le

AcQ

Map P

atient E

lectr

ode K

it

AcQ

Bla

te F

OR

CE

Se

nsin

g C

ath

ete

r

Qu

bic

Fo

rce

Mo

du

le

Qio

na

Irr

iga

tion

Pu

mp

Qu

bic

RF

Ge

ne

rato

r / C

on

tro

ller

Pu

lse

d F

ield

Ab

latio

n S

yste

m

No

t Y

et

Dis

clo

se

d

Not Y

et

Dis

clo

sed

No

t Y

et

Dis

clo

se

d

US

INT*

CommercialInvestigational Device or pending

approval/clearance in relevant markets Development

Our Journey to Become a Leading Electrophysiology Therapy Management Company

*Includes Acutus Direct Europe business and distribution markets through Biotronik

// 12 April 2021STRICTLY PRIVATE & CONFIDENTIAL 12

Grow installed base

We view our available market as

including every EP lab – this is not a

replacement market

X X

Increase procedures

per system per week

Convert multiple EP physicians

(and fellows) in each account

Spread usage across all arrhythmia

types -- from simple to complex,

including ventricular

Expand revenue

per procedure

Patient

Electrode

Patches

High-

Density

Mapping

Access Force

Sensing

Point

Ablation

Full Suite

of Septal

Crossing

Products

Diagnostic

Catheters

Fu

ture

To

day

Concentrated customer base in the U.S.*

~1,000EPs

~750Hospitals

& ~400kcardiac ablation

procedures each year

&

Model and Key Revenue DriversUp to $10K* revenue potential for disposables / procedure

*Data and analysis based on internal estimates

//

2021 Selected Catalysts and Key Milestones

12 April 2021 13

Initiation of AcQBlate Force Sensing Ablation Catheter US IDE for Right Atrial Flutter

US 510K clearance for the expanded family of AcQCross Integration Needle/Dilator

transseptal crossing devices

AcQMap 2.0 next generation mapping catheter CE Mark Approval

Data and abstract presentations at the annual Heart Rhythm Society Meeting

First-in-man and pilot trial work for Pulse Field Ablation (PFA)

Initiation of AcQBlate Force Sensing Ablation Catheter US IDE for Atrial Fibrillation

Completed Milestones Pending Developments

//

Several Factors Drive 2021 Sales Ramp

12 April 2021 14

Underlying market conditions and moderating impact of COVID restrictions

Manufacturing ramp for AcQBlate and transseptal access products

Timing of capital sales and conversions

Revenue uptake for anticipated new product approvals and launches

Improved US commercial execution

*We are not commenting on the quarter or outlook and will provide an update on financial performance on our May 12 th earnings call

Guidance as of Q4 Earnings Call*

1Q2021: $2.6-3.0 million FY2021: $22.0-30.0 million

//

Creating Long-term Shareholder Value

12 April 2021 15

• Internal R&D teams are

consistently delivering market-

relevant and differentiated new

products

• Augment organic efforts through

select licensing and partnership

opportunities

• Leadership changes bringing the

right capabilities to our team

• Training and developing our therapy

managers to support technology

and new product adoption

• Biotronik partnership extends our

access to global market

• Manufacturing footprint supports

long-term growth

• Gross margins should improve

meaningfully with scale

• Managing expenses to maximize

allocation to growth-oriented

investments

Technology

and Innovation

Leadership

Commercial

Execution

Operational

Excellence

Comprehensive Portfolio

and Robust Pipeline

Drive Adoption and

Shift the Paradigm

Well-Positioned for

Long-Term Scale

We will execute our strategy and drive shareholder value through:

//

Stay Connected with Acutus

12 April 2021 16

IssuerAcutus Medical, Inc.

Exchange / TickerNASDAQ: AFIB

Investor ContactCaroline Corner

415-202-5678

caroline.corner@westwicke.com

@AcutusMedical

linkedin.com/company/acutus-medical-inc-/

@AcutusMedical

Acutus Medical

acutus.com